To investigate metastatic castration resistant prostate cancer patients treated with Abiraterone and/or Abiraterone and Enzalutamide associated with development of liver metastases

Trial Profile

To investigate metastatic castration resistant prostate cancer patients treated with Abiraterone and/or Abiraterone and Enzalutamide associated with development of liver metastases

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Abiraterone (Primary) ; Enzalutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 New trial record
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top